Navigation Links
NIAID Initiates Trial of Experimental Avian Flu Vaccine

Fast-track recruitment has begun for a trial to investigate the safety of a vaccine against H5N1 avian influenza, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today.

Sites in Rochester, NY, Baltimore and Los Angeles will enroll a total of 450 healthy adults. The clinical sites are part of the NIAID-sponsored Vaccine and Treatment Evaluation Units (VTEU).

“While there have been relatively few cases worldwide of H5N1 avian influenza infection in humans, the public health community is concerned that the virus will develop the capability of efficiently spreading from human to human and thus create a risk for a worldwide pandemic,?says NIAID Director Anthony S. Fauci, M.D.

“NIAID has supported research on H5N1, the strain responsible for this deadly form of avian influenza, since 1997 when the first cases in humans were reported. The initiation of this vaccine trial marks a key advance in our efforts to prepare to respond to an avian flu pandemic,?adds Dr. Fauci.

Sanofi pasteur, Swiftwater, PA, manufactured the trial vaccine, which is an inactivated vaccine made from an H5N1 virus isolated in Southeast Asia in 2004. Sanofi pasteur, formerly Aventis Pasteur, was awarded a contract by NIAID to manufacture the H5N1 vaccine in May 2004.

This Phase I trial will test the vaccine’s safety and ability to generate an immune response in 450 healthy adults aged 18 to 64. If the vaccine is shown to be safe in adults, there are plans to test it in other populations, such as the elderly and children.

H5N1 avian influenza leads to severe disease in both birds and humans. Between January 2004 and March 11, 2005, there were 69 confirmed cases of and 46 deaths from H5N1 infection in humans reported to the World Health Organization. To date, there has been a small number of cases where human-to-human transmission of the virus may have occurred. However, public hea lth experts fear that the virus may evolve into one that is more easily transmitted between people. If this were to happen, a worldwide pandemic could follow.

Influenza pandemics are global outbreaks that emerge infrequently and unpredictably and involve strains of virus to which humans have little or no immunity. H5N1 is one such flu virus strain. The last influenza pandemic swept the globe in 1968; many public health officials believe the world is overdue for another one.

The VTEUs now enrolling adult volunteers are

* University of California at Los Angeles (Joel Ward, M.D., Principal Investigator)
* University of Maryland School of Medicine, Baltimore, MD (James Campbell, M.D., P.I.)
* University of Rochester School of Medicine and Dentistry, Rochester, NY (John Treanor, M.D., P.I.)

In addition to the previous contract awarded to sanofi pasteur, in May 2004 NIAID also awarded a contract to Chiron Corporation of Emeryville, CA, to produce H5N1 vaccine for clinical trials.


'"/>

Source:NIAID


Related biology news :

1. NIAID begins clinical trial of West Nile virus vaccine
2. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
3. NIAID researchers show how promising TB drug works
4. NIAID DNA vaccine for H5N1 avian influenza enters human trial
5. NIAID expands capability for influenza research and surveillance
6. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
7. Bird Brains Show How Trial and Error May Contribute to Learning
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
10. Trial success for diabetic nerve therapy
11. Trials for new drug to overcome HIV
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman Carl ... executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and ... Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, ...
(Date:8/7/2020)... , ... August 06, 2020 , ... ... participate in the prestigious National STEM Scholar Program, a unique professional development program ... and project support for middle school science teachers nationwide. , Created in partnership ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski ... with a near term focus on Type 2 diabetes and associated comorbidities. , ... multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and ... a great surgery is only the beginning of a successful study, while protecting and ... Join Brad Gien, Global Head of Surgery from Envigo in a ...
(Date:7/10/2020)... LORTON, Va. (PRWEB) , ... July 08, 2020 ... ... laboratory testing services and products, announces a significant expansion of laboratory operations through ... robust collection for agencies implementing testing programs. , Bode-CARES provides ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem cell ... million stem cells. Depending on the patient's condition, treatment may be offered IV, intrathecal ... having some form of Alzheimers dementia, and the incidence continues to increase as individuals ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
Breaking Biology Technology: